DrugPatentWatch Database Preview

Pfizer Company Profile

Email this page to a colleague

PFIZER has one hundred and thirty-seven approved drugs.

There are forty-eight US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.

There are one thousand two hundred and eighty-five patent family members on PFIZER drugs in seventy-six countries and two hundred and thirteen supplementary protection certificates in eighteen countries.

International Patents:	1285
US Patents:	48
Tradenames:	104
Ingredients:	98
NDAs:	137
Drug Master File Entries:	3
Patent Litigation for Pfizer:	See patent lawsuits for Pfizer
PTAB Cases with Pfizer as petitioner:	See PTAB cases with Pfizer as petitioner

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	CADUET	amlodipine besylate; atorvastatin calcium	TABLET;ORAL	021540-008	Jan 30, 2004	AB	RX	Yes	Yes		Start Trial				Start Trial
Pfizer	CEFOBID	cefoperazone sodium	INJECTABLE;INJECTION	050551-001	Nov 18, 1982		DISCN	No	No		Start Trial				Start Trial
Pfizer Inc	DAURISMO	glasdegib maleate	TABLET;ORAL	210656-002	Nov 21, 2018		RX	Yes	Yes	8,148,401	Start Trial	Y	Y		Start Trial
Pfizer	PFIZERPEN-AS	penicillin g procaine	INJECTABLE;INJECTION	060286-001	Approved Prior to Jan 1, 1982		DISCN	No	No		Start Trial				Start Trial
Pfizer	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-002	Nov 2, 1990	AB	RX	Yes	No		Start Trial				Start Trial
Pfizer	MINIZIDE	polythiazide; prazosin hydrochloride	CAPSULE;ORAL	017986-002	Approved Prior to Jan 1, 1982		DISCN	No	No		Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	CADUET	amlodipine besylate; atorvastatin calcium	TABLET;ORAL	021540-008	Jan 30, 2004	5,273,995*PED	Start Trial
Pfizer	TROVAN	trovafloxacin mesylate	TABLET;ORAL	020759-001	Dec 18, 1997	6,187,341	Start Trial
Pfizer Pharms	REZULIN	troglitazone	TABLET;ORAL	020720-003	Aug 4, 1997	6,011,049	Start Trial
Pfizer	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-001	Dec 30, 1991	4,536,518*PED	Start Trial
Pfizer Pharms	NEURONTIN	gabapentin	CAPSULE;ORAL	020235-002	Dec 30, 1993	4,024,175	Start Trial
Pfizer Pharms	REZULIN	troglitazone	TABLET;ORAL	020720-003	Aug 4, 1997	4,572,912	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Sublingual Tablets	0.3 mg, 0.4 mg and 0.6 mg	➤ Subscribe	2005-10-19
➤ Subscribe	Capsules	20 mg, 40 mg, 60 mg and 80 mg	➤ Subscribe	2005-02-07
➤ Subscribe	Capsules	0.125 mg, 0.25 mg, and 0.5 mg	➤ Subscribe	2014-05-01
➤ Subscribe	Tablets	150 mg and 200 mg	➤ Subscribe	2005-11-09
➤ Subscribe	Tablets	5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg and 10 mg/80 mg	➤ Subscribe	2006-12-29
➤ Subscribe	Tablets	2.5 mg/40 mg	➤ Subscribe	2009-09-17
➤ Subscribe	Injection	20 mg/mL, 2 mL and 5 mL vials	➤ Subscribe	2004-07-26
➤ Subscribe	Tablets	25 mg and 50 mg	➤ Subscribe	2004-11-19
➤ Subscribe	Tablets	20 mg and 40 mg	➤ Subscribe	2010-03-29
➤ Subscribe	Sublingual Tablets	0.6 mg	➤ Subscribe	2011-12-29
➤ Subscribe	Capsules	5 mg and 10 mg	➤ Subscribe	2005-06-21
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2011-06-17
➤ Subscribe	Extended-release Tablets	4 mg and 8 mg	➤ Subscribe	2012-10-31
➤ Subscribe	Tablets	5 mg/80 mg	➤ Subscribe	2009-04-07
➤ Subscribe	Capsules	75 mg, 100 mg and 125 mg	➤ Subscribe	2019-02-04
➤ Subscribe	Extended-release Tablets	11 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Tablets	100 mg	➤ Subscribe	2004-10-25

Patent Number	Expiration Date
Start Trial	Start Trial

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1746999	CR 2019 00043	Denmark	Start Trial	PRODUCT NAME: DACOMITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/19/1354 20190404
1507558	12C0033	France	Start Trial	PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705
0792290	0491022-0	Sweden	Start Trial	PRODUCT NAME: N EPSILONB29 MYRISTOYL- ELLER N EPSILONB29 TETRADEKANOYL-DES(B30) HUMANT INSULIN
2822953	301006	Netherlands	Start Trial	PRODUCT NAME: LORLATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/19/1355 20190508
0473687	3/1999	Austria	Start Trial	PRODUCT NAME: FOSPHENYTOIN-NATRIUM; NAT. REGISTRATION NO/DATE: 1-22664 19980728; FIRST REGISTRATION: GB 00019/0157 19980204
0473687	SPC/GB98/030	United Kingdom	Start Trial	PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.